Combination of cabazitaxel and plicamycin induces cell death in drug resistant B-cell acute lymphoblastic leukemia

B-cell acute lymphoblastic leukemia (ALL) manifests itself as an accumulation of poorly differentiated malignant lymphoid cells within the bone marrow (BM), resulting in the disruption of normal hematopoiesis [1]. BM is also the most common site of disease relapse, contributed by minimal residual disease (MRD), a major factor associated with poor prognosis and mortality [2]. Unlike T-cell lymphoblastic leukemia, MRD in ALL has been less completely studied and its etiology still remains to be more clearly delineated [3].

Source: Leukemia Research - August 6, 2018 Category: Hematology Authors: Rajesh R. Nair, Debbie Piktel, Werner J. Geldenhuys, Laura F. Gibson Source Type: research